Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series.
Tasnim AbdallaMark MansourDorra BouazziMichelle A LowesGregor Borut Ernst JemecAfsaneh AlaviPublished in: American journal of clinical dermatology (2020)
Patients with AAAs had significantly lower serum adalimumab levels. The current study suggests that TDM may identify underlying reasons for suboptimal response and detect patients who may benefit from dose optimization strategies.